Xista Science Ventures

Xista Science Ventures does not have its own clinical results but has invested in over 22 deep tech and life science startups across Europe. Portfolio highlights include synthetic biology platforms and novel protein conjugation technologies being developed by investee companies such as Valanx. "By means of synthetic biology and genetic code extension Valanx has developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest. Based on this platform Valanx is developing a number of cutting-edge biologics towards potential treatments for various indications."